For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast-conserving surgery and did not receive ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence in the ...

For patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive ...

Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient's gut microbiome can impact how effective the treatment is.

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus ...

Immediate surgery can improve outcomes among women age 70 and older who are not receiving radiotherapy, data suggest.

Today, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal ...

A recent study has revealed that the gut microbiome plays a critical role in tamoxifen’s metabolism, influencing its ...

Tamoxifen reduces the rate of breast cancer recurrence by approximately a half. Tamoxifen is metabolized to more active metabolites by enzymes encoded by polymorphic genes, including cytochrome ...

Tamoxifen is a common and important treatment to prevent breast cancer from recurring. A new study shows that variation in a patient’s gut microbiome can impact how effective the treatment is.

A new study has shown that variation in the microbiota of the human gut impacts the pharmacokinetics of tamoxifen and thus the effectiveness of the drug. The finding, published in the journal mBio of ...